Do Symptoms and Serum Calcium Levels Affect the Results of Surgical Treatment of Primary Hyperparathyroidism?
Table 6
Clinical data of group A and group B.
Index
Group A n=44
Group B n=153
P value
PHPT
22.34% (44/197)
77.66% (153/197)
Age (y) ± SD
46.00 ± 12.30
49.43 ± 12.35
0.106
Sex
0.948
male
25.00% (11/44)
25.49% (39/153)
female
75.00% (33/44)
74.51% (114/153)
Preoperative PTH
1025.54 ± 887.69
657.10 ± 806.75
0.01
Preoperative AKP
456.45 ± 551.29
221.70 ± 248.84
0.008
Preoperative Ca
3.01 ± 0.40
2.93 ± 0.48
0.297
Preoperative P
0.80 ± 0.24
0.95 ± 0.38
0.003
SPHPT
84.09% (37/44)
33.99% (52/153)
< 0.0001
Symptom type I
0.007
Single symptoms
40.54%(15/37)
69.23%(36/52)
Multiple symptoms
59.46%(22/37)
30.77%(16/52)
Symptom type II
nephrolithiasis
56.82%(25/44)
11.76%(18/153)
< 0.0001
osseous lesion
52.27%(23/44)
14.38%(22/153)
< 0.0001
gastrointestinal symptoms
9.09%(4/44)
7.84%(12/153)
0.759
others
18.18%(8/44)
11.76%(18/153)
0.268
Group A: Patients who have been treated for 2008-2012; Group B: Patients who have been treated for 2013-2017. Abbreviations: PHPT, primary hyperparathyroidism; PTH, parathyroid hormone; AKP, alkaline phosphatase.
